Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

111.07 -1.23 (-1.10%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Monkeypox vaccine and research related stocks taking center stage (VRAX,GOVX,TNXP,APDN)
Via AB Newswire
Exposures COVID-19
Merck Reports Strong Progress in ESG Focus Areas
From Merck & Co., Inc.
Via Business Wire
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
From Merck & Co., Inc.
Via Business Wire
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
From Merck & Co., Inc.
Via Business Wire
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
From Merck & Co., Inc.
Via Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
The Power of Science to Stop a Killer
Via Investor Brand Network
The Power of Science to Stop a Killer
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114... 
Via FinancialNewsMedia
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Second-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Announces Fourth-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Three Watchlist Stocks to Capitalize on Sector Rotation
Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a... 
Via MarketBeat
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
From Merck & Co., Inc.
Via Business Wire
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
From Merck & Co., Inc.
Via Business Wire
Tackling Recurring Health Conditions Offers Hope to Patients
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.